Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Boundless Bio, Inc.

Get SEC filing alerts via email and in your feed for Boundless Bio, Inc.

BOLD

Boundless Bio, Inc.

About Boundless Bio, Inc.

Boundless Bio, Inc. is a clinical-stage oncology company focused on developing therapies targeting extrachromosomal DNA (ecDNA), a key driver of oncogene amplification in cancer. Its proprietary platform identifies vulnerabilities in ecDNA biology to create small molecule ecDNA-directed therapeutics (ecDTx). The company's lead drug, BBI-355, a CHK1 inhibitor, aims to treat ecDNA-driven cancers resistant to existing therapies, addressing a significant unmet medical need across multiple tumor types.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Boundless Bio, Inc.

1
1
Boundless Bio, Inc. Boundless Bio Reports $13.6 Million Net Loss in Q1 2026, Reduces Operating Expenses

Via official filing (AI summary) | 28 days ago | 0 comments

2
1
Boundless Bio, Inc. Boundless Bio Reports $58.2 Million Net Loss for 2025, Focuses on BBI-940 Program

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Boundless Bio, Inc. Boundless Bio Reports Q3 2025 Financial Results with Reduced Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Boundless Bio, Inc. Boundless Bio Reports Q2 2025 Financial Results with $15.7 Million Net Loss

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Boundless Bio, Inc. Boundless Bio Reports $15.8 Million Net Loss in Q1 2025, Cash Reserves Decline

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Boundless Bio, Inc. Boundless Bio Reports $65.36 Million Net Loss for 2024, Discontinues BBI-825 Trial

Via official filing (AI summary) | about 1 year ago | 0 comments